Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurizio Zazzi

Showing results (1-10 of 249) with videos related to

Pageof 25
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2010
High genetic barrier antiretroviral drugs in human immunodeficiency virus-positive pregnancyMaurizio Zazzi
AIDS (London, England)|February 10, 2018
Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from dual therapy studiesDiego Ripamonti, Maurizio Zazzi
The Lancet. HIV|September 15, 2023
Emergent HIV drug resistance in non-inferiority trialsDiego Ripamonti, Maurizio Zazzi
The Journal of Infectious Diseases|January 11, 2015
Interplay Between Transmitted and Acquired HIV Type 1 Drug Resistance: Reasons for a DisconnectAndrea De Luca, Maurizio Zazzi
AIDS (London, England)|December 20, 2023
A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirineDiego Ripamonti, Stefano Rusconi, Maurizio Zazzi
Peerj|May 31, 2018
The global burden of HIV-1 drug resistance in the past 20 yearsMaurizio Zazzi, Hui Hu, Mattia Prosperi
Expert Opinion on Therapeutic Patents|January 21, 2021
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19Ilaria Vicenti, Maurizio Zazzi, Francesco Saladini
The Journal of Antimicrobial Chemotherapy|July 27, 2024
Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirineDiego Ripamonti, Alberto Borghetti, Maurizio Zazzi
Journal of Medical Virology|June 10, 2003
Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapyElena Chiappini, Luisa Galli, Maurizio Zazzi, et al.
Current HIV Research|October 30, 2015
Computer-Aided Optimization of Combined Anti-Retroviral Therapy for HIV: New Drugs, New Drug Targets and Drug ResistanceMaurizio Zazzi, Alessandro Cozzi-Lepri, Mattia C F Prosperi
Pageof 25

Showing results (1-10 of 249) with videos related to

Sort By:
Pageof 25
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2010
High genetic barrier antiretroviral drugs in human immunodeficiency virus-positive pregnancyMaurizio Zazzi
AIDS (London, England)|February 10, 2018
Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from dual therapy studiesDiego Ripamonti, Maurizio Zazzi
The Lancet. HIV|September 15, 2023
Emergent HIV drug resistance in non-inferiority trialsDiego Ripamonti, Maurizio Zazzi
The Journal of Infectious Diseases|January 11, 2015
Interplay Between Transmitted and Acquired HIV Type 1 Drug Resistance: Reasons for a DisconnectAndrea De Luca, Maurizio Zazzi
AIDS (London, England)|December 20, 2023
A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirineDiego Ripamonti, Stefano Rusconi, Maurizio Zazzi
Peerj|May 31, 2018
The global burden of HIV-1 drug resistance in the past 20 yearsMaurizio Zazzi, Hui Hu, Mattia Prosperi
Expert Opinion on Therapeutic Patents|January 21, 2021
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19Ilaria Vicenti, Maurizio Zazzi, Francesco Saladini
The Journal of Antimicrobial Chemotherapy|July 27, 2024
Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirineDiego Ripamonti, Alberto Borghetti, Maurizio Zazzi
Journal of Medical Virology|June 10, 2003
Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapyElena Chiappini, Luisa Galli, Maurizio Zazzi, et al.
Current HIV Research|October 30, 2015
Computer-Aided Optimization of Combined Anti-Retroviral Therapy for HIV: New Drugs, New Drug Targets and Drug ResistanceMaurizio Zazzi, Alessandro Cozzi-Lepri, Mattia C F Prosperi
Pageof 25